Drug intelligence / Profile preview

SPSO 1006

Development stage: Unknown
Lead developer: Spriaso

Overview

SPSO 1006 is an investigational drug candidate developed by Spriaso for the treatment of gastrointestinal (GI) disorders. It is currently in the pre-clinical to early clinical stage of development. Spriaso focuses on the development of specialty pharmaceuticals for central nervous system (CNS) and gastrointestinal conditions, utilizing unique products and delivery platforms designed to improve patient compliance. While the company has indicated that its pipeline products have completed proof-of-principle clinical studies, specific details regarding the molecular target, mechanism of action, or chemical modality of SPSO 1006 have not been publicly disclosed.

Beyond the preview

Go deeper on SPSO 1006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPSO 1006.

Explore the full profile